BioCatalystWatch
GMABWorkspace / GMAB / OverviewCompany library
Price
Market cap
Next catalystDec 12, 2026epcoritamab-bysp · Phase 2 dataCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

Epcoritamab

CD3 × CD20

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

Epcoritamab

CD3 × CD20

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

Petosemtamab

EGFR × LGR5

PreINDP1P2P3FilingApproved
Upcoming / outlook

Petosemtamab

EGFR × LGR5

PreINDP1P2P3FilingApproved
Upcoming / outlook

Petosemtamab

EGFR × LGR5

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

Epcoritamab

CD3 × CD20

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

Petosemtamab

EGFR × LGR5

PreINDP1P2P3FilingApproved
Upcoming / outlook

Epcoritamab

CD3 × CD20

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

Petosemtamab

EGFR × LGR5

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

GEN1059 (BNT314)

EpCAM × 4-1BB (CD137)

PreINDP1P2P3FilingApproved
Epcoritamab

CD3 × CD20

PreINDP1P2P3FilingApproved
Petosemtamab

EGFR × LGR5

PreINDP1P2P3FilingApproved

FRα

PreINDP1P2P3FilingApproved
Rina-S®

FRα

PreINDP1P2P3FilingApproved

Petosemtamab

EGFR × LGR5

PreINDP1P2P3FilingApproved
Petosemtamab

EGFR × LGR5

PreINDP1P2P3FilingApproved
Petosemtamab

EGFR × LGR5

PreINDP1P2P3FilingApproved
Petosemtamab

EGFR × LGR5

PreINDP1P2P3FilingApproved

Partner / License out

GEN1059 (BNT314)

EpCAM × 4-1BB (CD137)

OX40 (CD134)

PreINDP1P2P3FilingApproved

Approved / commercial

CD38

Approved

PreINDP1P2P3FilingApproved

CD3 × BCMA

Approved

PreINDP1P2P3FilingApproved
Epcoritamab

CD3 × CD20

PreINDP1P2P3FilingApproved
Upcoming / outlook

Epcoritamab

CD3 × CD20

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Epcoritamab

CD3 × CD20

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

CD20

Approved

PreINDP1P2P3FilingApproved

CD38

Approved

PreINDP1P2P3FilingApproved

CD38

Approved

PreINDP1P2P3FilingApproved

History / paused

Financial position

Short-term investments

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

GMAB SEC archive